Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.

Wei Z, Zhang X, Yong T, Bie N, Zhan G, Li X, Liang Q, Li J, Yu J, Huang G, Yan Y, Zhang Z, Zhang B, Gan L, Huang B, Yang X. · 2021

Read Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. by Wei Z, Zhang X, Yong T, Bie N, Zhan G, Li X, Liang Q, Li J, Yu J, Huang G, Yan Y, Zhang Z, Zhang B, Gan L, Huang B, Yang X. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7815730.txt.

Introduction

Wei and co-authors build microparticles that boost anti-PD-1 therapy for cancer. Checkpoint drugs face three barriers. Too few T cells enter the tumor. The tumor setting suppresses immunity. Antibodies gather and sink into tumors poorly.

The particles come from macrophage membranes. They carry the drug metformin and wear a mannose coat. That coat steers them to M2-like tumor macrophages. Metformin then flips those cells to the attack-minded M1 form. Flipped macrophages drew in more CD8+ T cells. Suppressive cell types fell back. The particles also broke down collagen in the tumor. Anti-PD-1 antibody then reached deeper and worked better. Treated animals gained stronger, longer-lasting tumor control.

Catalog record

CREATORWei Z, Zhang X, Yong T, Bie N, Zhan G, Li X, Liang Q, Li J, Yu J, Huang G, Yan Y, Zhang Z, Zhang B, Gan L, Huang B, Yang X.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE98 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7815730

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles By Zhaohan Wei, Xiaoqiong Zhang, Tuying Yong, Nana Bie, Guiting Zhan, Xin Li, Qingle Liang, Jianye Li, Jingjing Yu, Gang Huang, Yuchen Yan, Zelong Zhang Published in: Nature Communications DOI: 10.1038/s41467-020-20723-x ABSTRACT Abstract The main challenges for programmed cell death 1(PD-1)/PD-1 ligand (PD-L1) checkpoint blockade lie in a lack of sufficient T cell infiltration, tumor immunosuppressive microenvironment, and the inadequate tumor accumulation and penetration of anti-PD-1/PD-L1 antibody. Resetting tumor-associated macrophages (TAMs) is a promising strategy to enhance T-cell antitumor immunity and ameliorate tumor immunosuppression. Here, mannose-modified macrophage-derived microparticles (Man-MPs) loading metformin (Met@Man-MPs) are developed to efficiently target to M2-like TAMs to repolarize into M1-like phenotype. Met@Man-MPs-reset TAMs remodel the tumor immune microenvironment by increasing the recruitment of CD8+ T cells into tumor tissues and decreasing immunosuppressive infiltration of myeloid-derived suppressor cells and regulatory T cells. More importantly, the collagen-degrading capacity of Man-MPs contributes to the infiltration of CD8+ T cells into tumor interiors and enhances tumor accumulation and penetration of anti-PD-1 antibody. These unique features of Met@Man-MPs contribute to boost anti-PD-1 antibody therapy, improving anticancer efficacy and long-term memory immunity after combination treatment. Our results support Met@Man-MPs as a potential drug to improve tumor resistance to anti-PD-1 therapy. Subject terms: Bioinspired materials, Biomedical materials, Drug delivery, Cancer microenvironment, Cancer therapy INTRODUCTION Programmed cell death 1(PD-1)/PD-1 ligand (PD-L1) checkpoint blockade is a promising clinical anticancer treatment modality by blocking the binding of PD-L1 on tumor cells to PD-1 on activated T cells to reactivate T-cell-mediated antitumor immunity1–3. However, the durable response rate to anti-PD-1/PD-L1 therapy remains relatively low in most cases4,5. The major factors attributed to the resistance to anti-PD-1/PD-L1 therapy include the lack of infiltrating T lymphocytes in tumor tissues characterizing the so-called “cold tumor”6, and the presence of tumor immunosuppressive microenvironment, such as regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs) to inhibit the anti-PD-1/PD-L1 antibody-regenerated anti-tumor cytotoxic T lymphocytes and Th1 cell response7,8. In addition, the aberrant vascular architecture, elevated interstitial fluid pressure, and compact extracellular matrix (ECM) in tumor tissues hamper the tumor accumulation of anti-PD-1/PD-L1 antibody and subsequent deep penetration into tumor parenchyma9,10, which limits the therapeutic effects of anti-PD-1/PD-L1 antibody. Therefore, efficient T lymphocyte tumor infiltration, improved tumor immunosuppressive microenvironment, and enhanced tumor accumulation and penetration of anti-PD-1/PD-L1 antibody are required to increase the potential responses to anti-PD-1/PD-L1 antibody. Tumor-associated macrophages (TAMs), one of the most abundant tumor-infiltrating leukocytes in various tumors, are commonly educated by tumor microenvironment to different phenotypes11,12. M1-like TAMs, recognized as classically activated macrophages, exhibit anticancer activity by releasing nitrogen oxide (NO) and stimulating naïve T cells to make a Th1/cytotoxic response13. In contrast, M2-like TAMs, alternatively activated macrophages predominantly present in tumors, promote tumor growth, angiogenesis, metastasis and tumor immune escape14. M2-like TAMs can directly or indirectly inhibit T cell functions by expressing T cell immune checkpoint ligands (such as PD-L1 and PD-L2)15,16, secreting inhibitory cytokines (such as IL-10 and transforming growth factor-β)17, and recruiting immunosuppressive cells (such as Treg cells)18. Therefore, repolarization of M2-like TAMs to M1 phenotype is a promising strategy to improve the T cell-mediated antitumor immunity and ameliorate the immunosuppressive tumor microenvironment, which might be beneficial for the enhanced anticancer activity of anti-PD-1/PD-L1 antibody. Metformin (Met), a popular drug used to treat diabetes due to its good hypoglycemic effect, few side effects, and low cost19, exhibits anticancer activity20. A large number of studies have shown that Met can regulate tumor metabolism21, arrest tumor cell cycle22, inhibit angiogenesis23, and kill cancer stem cells by activating adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK)24. Recently, Met has been found to efficiently repolarize M2-like TAMs to M1 phenotype to inhibit tumor growth and metastasis through the AMPK-NF-κB signaling pathway25,26. However, how to achieve the targeted delivery of Met to M2-like TAMs to further improve the therapeutic effects remains a big challenge. Cellular microparticles (MPs) are extracellular vesicles with a diameter of 100–1000 nm that are shed by cells in response to various endogenous or exogenous stimuli27–29. MPs hold great potential as drug-delivery systems due to the unique property to deliver messenger molecules, enzymes, and genetic material (DNAs, RNAs) between cells30–32, and the superior circulation stability, high biocompatibility, low immunogenicity and toxicity33–35. Considering that TAMs are derived from monocytes or tissue-resident macrophages recruited by various signals in the tumor microenvironment (such as cytokines, chemokines, ECM components, and hypoxia, etc.)14,36, macrophage-derived MPs have natural tumor-targeting capacity37. M2-like TAMs highly express mannose receptor CD206/MRC138,39. In this study, mannose (Man)-modified macrophage-derived MPs are used as carriers for targeted delivery of Met (denoted as Met@Man-MPs) to M2-like TAMs. Met@Man-MPs efficiently reset TAMs toward M1 phenotype to inhibit tumor growth. Importantly, Met@Man-MPs significantly improve tumor immunosuppressive microenvironment, and enhance CD8+ T cell infiltration into tumor interiors by the reset macrophages-induced recruitment of CD8+ T cells and Man-MPs-induced tumor ECM degradation since macrophages express matrix metalloproteinases (MMPs)40,41. Meanwhile, Met@Man-MPs efficiently enhance tumor accumulation and penetration of anti-PD-1 antibody. These unique features of Met@Man-MPs contribute to the anticancer treatment of anti-PD-1 antibody, resulting in strong anticancer efficacy and the generation of long-term memory immunity after co-administration (Fig. 1a). [Figure: Characterization of [email protected] Schematic of Met@Man-MPs as an efficient drug to boost anti-PD-1 therapy. Met@Man-MPs with MMP activity efficiently target to M2-like TAMs and degrade tumor collagen. (1) Met@Man-MPs repolarize M2-like TAMs to M1-like phenotype, resulting in the recruitment of CD8+ T cells into tumor tissues and the ameliorated tumor immunosuppressive microenvironment. (2) Collagen-degrading capacity of Man-MPs contributes to the infiltration of CD8+ T cells into tumor interiors and enhances tumor accumulation and penetration of anti-PD-1 antibody. (3) Met@Man-MPs synergistically inhibit tumor growth in combination with anti-PD-1 antibody, generating long-term memory immunity. b Hydrodynamic diameters of MPs and Man-MPs with or without Met by DLS analysis. Polydispersity index values are indicated in the brackets. c Zeta potentials of MPs and Man-MPs with or without Met by DLS analysis. Data are presented as means ± s.d. (n = 3 independent samples). d Morphology of MPs and Man-MPs with or without Met by TEM. Images are representative of three independent experiments. Scale bars: 500 nm. e Drug release of Met@MPs and Met@Man-MPs in PBS at different pH values. Data are presented as means ± s.d. (n = 3 independent samples). Source data are provided as a Source Data file.] RESULTS Preparation and characterization of Met@Man-MPs M2-like macrophages highly expressed Mrc1 gene (Supplementary Fig. 1), which encoded mannose receptor CD206/MRC1. To acquire Man-modified MPs to achieve M2-like macrophage targeting, murine RAW264.7 macrophages were first incubated with DSPE-PEG-Man to obtain Man-engineered cells by virtue of the natural membrane phospholipid exchange of cells42. RAW264.7 cells and Man-engineered RAW264.7 cells were then treated with Met (2 mg mL−1), followed by ultraviolet irradiation for Met-packaging MPs and Man-MPs (denoted as Met@MPs and Met@Man-MPs, respectively) induction34,35. Lectin recognition assay confirmed the successful modification of Man in Man-MPs and Met@Man-MPs (Supplementary Fig. 2). Dynamic light scattering (DLS) analysis showed that Met@MPs and Met@Man-MPs have a similar size of 440 nm (Fig. 1b) and zeta potential of −11.6 mV (Fig. 1c), respectively. Transmission electron microscopy (TEM) revealed that both Met@MPs and Met@Man-MPs were monodisperse and irregularly spherical (Fig. 1d). High-performance liquid chromatography (HPLC) analysis showed that the drug loading capacity for both

Read the complete text